Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

Br J Haematol. 2013 Jan;160(2):171-6. doi: 10.1111/bjh.12102. Epub 2012 Nov 15.


This report represents a further update of the consensus panel criteria for the assessment of clinical response in patients with Waldenström macroglobulinaemia (WM). These criteria have been updated in light of further data demonstrating an improvement in categorical responses with new drug regimens as well as acknowledgement of the fact that such responses are predictive of overall outcome. A number of key changes are proposed but challenges do however remain and these include the variability in kinetics of immunoglobulin M (IgM) reduction with different treatment modalities and the apparent discrepancy between IgM and bone marrow/tissue response noted with some regimens. Planned sequential bone marrow assessments are encouraged in clinical trials.

Publication types

  • Consensus Development Conference
  • Practice Guideline

MeSH terms

  • Antibodies, Monoclonal / blood
  • Antibodies, Monoclonal / therapeutic use
  • Antimetabolites / therapeutic use
  • Bone Marrow Examination / methods
  • Bone Marrow Examination / standards
  • Boronic Acids / therapeutic use
  • Bortezomib
  • Densitometry
  • Disease Progression
  • Disease-Free Survival
  • Forecasting
  • Hematopoiesis
  • Humans
  • Immunoglobulin Light Chains / blood
  • Immunoglobulin M / blood
  • Immunosuppressive Agents / therapeutic use
  • Neoplasm, Residual
  • Nephelometry and Turbidimetry
  • Positron-Emission Tomography
  • Pyrazines / therapeutic use
  • Remission Induction
  • Survival Analysis
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Waldenstrom Macroglobulinemia / blood
  • Waldenstrom Macroglobulinemia / drug therapy*
  • Waldenstrom Macroglobulinemia / pathology


  • Antibodies, Monoclonal
  • Antimetabolites
  • Boronic Acids
  • Immunoglobulin Light Chains
  • Immunoglobulin M
  • Immunosuppressive Agents
  • Pyrazines
  • Bortezomib